Triad Therapeutics Combines Structural Proteomics and Smart Chemistry To Accelerate Small Molecule Drug Discovery From Years to Weeks

Company Presents IOPE(TM) High Throughput Drug Design Technology at Drug

Discovery Technology Europe Conference



Apr 24, 2001, 01:00 ET from Triad Therapeutics, Inc.

    STUTTGART, Germany, April 24 /PRNewswire Interactive News Release/ --
 Triad Therapeutics, Inc., today presented IOPE(TM), its high throughput
 structure-based drug design technology, as a solution to the chemistry
 bottleneck of post-genomics drug discovery at "Drug Discovery Technology
 Europe 2001" in Stuttgart, Germany.  IOPE combines structural proteomics and
 smart chemistry to enable the discovery of high quality small molecule drug
 leads within weeks for key gene families that are rich in drug targets.
     Genomics research is providing the pharmaceutical industry with an
 abundance of new drug targets.  A major challenge now is to improve upon
 conventional combinatorial chemistry and structure-based drug design efforts
 in order to increase the productivity of drug discovery and development.
     "IOPE brings speed and focus to drug discovery by enabling the parallel
 construction of small molecule inhibitors for all protein targets within a
 given gene family," said Stephen Coutts, President and Chief Operating Officer
 at Triad Therapeutics.  "We are leveraging proteomics to synthesize drugs for
 whole families of protein targets even before disease links to the targets are
 identified."
     Dr. Coutts presented details of IOPE (Integrated Object-Oriented
 PharmacoEngineering), explaining the technology's focus on constructing drugs
 with two hooks, or ligands, that interact with protein targets in two binding
 sites.  This bi-ligand approach enables Triad to combine structure-based
 rational design with the diversity of combinatorial chemistry to make
 bi-ligand molecules with higher binding affinity and selectivity for their
 targets compared to molecules that interact with protein targets in only one
 site.
     IOPE is based on a novel application of nuclear magnetic resonance
 spectroscopy (NMR) to guide drug design. Knowledge of the interaction between
 a protein and ligand gathered through NMR enables Triad to determine the best
 position to place a linker between the two ligands.
     "With IOPE, NMR is no longer simply a validation step used by medicinal
 chemists after a drug has already been designed and synthesized," said Dr.
 Coutts.  "Triad is the first company to synergistically combine NMR,
 structure-based drug design and combinatorial chemistry to synthesize drugs
 that better fit and inhibit their targets.  We can do this with unprecedented
 speed by examining only the protein-ligand interaction as opposed to solving
 entire protein structures."
     Triad recently reported validation of IOPE (see Company press release
 dated February 14, 2001) and is currently constructing a collection of
 bi-ligand inhibitors for its first gene family.
     The Company plans to develop several leads for its own account, as well as
 form partnerships with pharmaceutical and biotechnology customers for whom
 Triad's technology enables a jump from the partner's validated targets to
 nanomolar-level chemical leads in just a few weeks.
     Triad Therapeutics, Inc., is headquartered in San Diego, California.  For
 more information on Triad Therapeutics, Inc., please visit
 www.triadtherapeutics.com.
 
     IOPE(TM) is a trademark of Triad Therapeutics, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X53336842
 
 

SOURCE Triad Therapeutics, Inc.
    STUTTGART, Germany, April 24 /PRNewswire Interactive News Release/ --
 Triad Therapeutics, Inc., today presented IOPE(TM), its high throughput
 structure-based drug design technology, as a solution to the chemistry
 bottleneck of post-genomics drug discovery at "Drug Discovery Technology
 Europe 2001" in Stuttgart, Germany.  IOPE combines structural proteomics and
 smart chemistry to enable the discovery of high quality small molecule drug
 leads within weeks for key gene families that are rich in drug targets.
     Genomics research is providing the pharmaceutical industry with an
 abundance of new drug targets.  A major challenge now is to improve upon
 conventional combinatorial chemistry and structure-based drug design efforts
 in order to increase the productivity of drug discovery and development.
     "IOPE brings speed and focus to drug discovery by enabling the parallel
 construction of small molecule inhibitors for all protein targets within a
 given gene family," said Stephen Coutts, President and Chief Operating Officer
 at Triad Therapeutics.  "We are leveraging proteomics to synthesize drugs for
 whole families of protein targets even before disease links to the targets are
 identified."
     Dr. Coutts presented details of IOPE (Integrated Object-Oriented
 PharmacoEngineering), explaining the technology's focus on constructing drugs
 with two hooks, or ligands, that interact with protein targets in two binding
 sites.  This bi-ligand approach enables Triad to combine structure-based
 rational design with the diversity of combinatorial chemistry to make
 bi-ligand molecules with higher binding affinity and selectivity for their
 targets compared to molecules that interact with protein targets in only one
 site.
     IOPE is based on a novel application of nuclear magnetic resonance
 spectroscopy (NMR) to guide drug design. Knowledge of the interaction between
 a protein and ligand gathered through NMR enables Triad to determine the best
 position to place a linker between the two ligands.
     "With IOPE, NMR is no longer simply a validation step used by medicinal
 chemists after a drug has already been designed and synthesized," said Dr.
 Coutts.  "Triad is the first company to synergistically combine NMR,
 structure-based drug design and combinatorial chemistry to synthesize drugs
 that better fit and inhibit their targets.  We can do this with unprecedented
 speed by examining only the protein-ligand interaction as opposed to solving
 entire protein structures."
     Triad recently reported validation of IOPE (see Company press release
 dated February 14, 2001) and is currently constructing a collection of
 bi-ligand inhibitors for its first gene family.
     The Company plans to develop several leads for its own account, as well as
 form partnerships with pharmaceutical and biotechnology customers for whom
 Triad's technology enables a jump from the partner's validated targets to
 nanomolar-level chemical leads in just a few weeks.
     Triad Therapeutics, Inc., is headquartered in San Diego, California.  For
 more information on Triad Therapeutics, Inc., please visit
 www.triadtherapeutics.com.
 
     IOPE(TM) is a trademark of Triad Therapeutics, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X53336842
 
 SOURCE  Triad Therapeutics, Inc.